Fifteen years ago, folks in the industry were buzzing about RNAi the way they talk about CRISPR today. Then things went quiet for the technology, at least in the news. Until last year.
In September of 2017, Alnylam Pharmaceuticals, the leader in the RNAi space, announced such positive phase III study results that most experts in the business expect an FDA approval soon. It will be the first for an RNAi drug.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
www.mendelspod.com/subscribe
Mendelspod Podcast